Acadia Pharmaceuticals
| File:Acaida logo.gif | |
| Public | |
| Traded as | NASDAQ: ACAD |
| Industry | Biopharmaceutical, Healthcare |
| Founded | 1993 |
| Headquarters | San Diego, CA, U.S. |
|
Key people
|
Dr. Uli Hacksell CEO |
| Products | Pimavanserin |
| Revenue |  $42.13M (2011) |
| $22.85M (2011) |
|
| $22.76M(2011) |
|
| Total assets | 108.71M (2012) |
|
Number of employees
|
95 [1] |
| Website | [2] |
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV [3] development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform.
Recent Events
Acadia Pharmaceuticals extended its drug discovery and development research agreement with Allergan to March 2012.[citation needed] The agreement stipulates both parties will work together for the discovery of new therapeutics for glaucoma and ophthalmic conditions.[4]
References
- ↑ http://www.utsandiego.com/news/2014/dec/29/acadia-pharmaceuticals-psychosis-drug-Nuplazid/
- ↑ http://www.acadia-pharm.com/
- ↑ http://www.utsandiego.com/news/2014/dec/29/acadia-pharmaceuticals-psychosis-drug-Nuplazid/
- ↑ http://finance.yahoo.com/news/Acadia-Pharma-extends-eye-apf-2862915783.html?x=0&.v=1 Acadia Pharma extends eye drug deal with Allergan
